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A twenty-one year old college student discovered she had a peanut
allergy at the age of three, when a classmate shared peanut-butter crackers
that led to a severe rash covering her body. Doctors quickly diagnosed this
reaction as a peanut allergy. Over the years the allergy reaction strengthened,
now she is allergic to not only peanuts but all nuts-even coconuts will
produce a mild allergic reaction. She carries an EpiPen with her always, close
friends carry one as well, and though she no longer lives at home her mother
still has an EpiPen 'just in case. " She has only needed to use the EpiPen once;
when she was a child and a waiter assured her the pieces ofcandy were "safe"
(a word she uses to denote what foods are not contaminated and not life-
threatening). In a matter of seconds, she began to feel her throat restrict and
within minutes her life was saved as her father injected the epinephrine into
her thigh. As Mylan increases the price on the drug she and others need,
EpiPens may not be available when needed most.
I. INTRODUCTION
Modem healthcare relies on the use of many different pharmaceutical
therapies. Physicians and patients have come to expect that their health will be
enhanced by prescriptions, including antibiotics and other drug technologies.
Obtaining and taking prescriptions has become so commonplace that
consumers are rarely faced with the reasoning behind the price and value of
the drug. It is only when the price becomes so high and hinders consumers'
ability to utilize the necessary prescription that individuals are forced to gather,
take actions, and play a role in the price-setting of prescription drugs.
Pharmaceutical companies hold great power within the healthcare
industry.' The creation of life-saving medications, and subsequent patents
create a controlling monopoly over the consumers and other parties that
distribute pharmaceuticals. 2 Though many individuals purchase and re-
purchase these drugs, it often feels as though the average consumer has little
to no buyer power to assert against pharmaceutical companies. And, without
buyer power, the pharmaceutical companies continue to set higher prices and
consumers have no choice but to accept.
' Erin Fox, How Pharma Companies Game the System to Keep Drugs Expensive,
Harvard Business Review, April 6, 2017, https://hbr.org/2017/04/how-pharma-companies-
game-the-system-to-keep-drugs-expensive.
2 Aaron Xavier Fellmeth, Secrecy, Monopoly, and Access to Pharmaceuticals in
International Trade Law: Protection of Marketing Approval Data Under the Trips
Agreement, 45 HARV. INT'L L.J. 443,446 (2004) (discussing that pharmaceutical industries
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Prescription drug pricing is complex and involves the input of many
different parties throughout society. Consumers, insurance companies, and
pharmaceutical manufacturers have differing and interacting interests, which
are not all acknowledged in the current price of pharmaceuticals. For example,
EpiPens provide a necessary utility to consumers but the high price makes it
difficult for some individuals with life-threatening allergies to obtain this life-
saving drug.3 There has been recent widespread media attention on the
continually climbing costs of prescription medications. Specifically, the
drastic price increase of Mylan's EpiPen caused consumers to begin seeking
solutions;' whether it is buying new generic epinephrine devices or joining a
class action lawsuit against Mylan.'
While a class action lawsuit assists in aggregating a consumer base to
increase buyer power, a more efficient resolution can be achieved with
alternative dispute resolution (ADR) methods like arbitration and mediation.
ADR focuses on complementing interests rather than competing positions and
can utilize a neutral party that will help leverage the buyer power of
consumers. Therefore, Mylan will perceive greater incentives to listen and
change their pricing methods in dispute resolution methods than in traditional
litigation methods. If consumers, through mediation and arbitration, can
maximize buyer power by gathering as one unit and fostering the interests of
all parties, cost-effective and productive prices of prescription drugs can be
created.
A class action arbitration or mediation, rather than traditional binary
litigation, allows drug manufacturers and the often-overlooked consumer to
develop strategies to lower prescription drug prices while protecting the
development costs of new and necessary drugs. The key to finding an effective
solution in a class action against Mylan is utilizing a process that promotes
flexibility, creativity, and more open communication. Mediation and
arbitration employs a neutral to weigh sides of the case, but to aid and resolve
the issue in a mutually-beneficial manner. Alternative dispute resolution opens
communication between the parties, therefore this class can demonstrate to
Mylan that their interests reflect the interests of the larger population that
creates the demand for the EpiPen and if there is no price-reduction these
3See Brad Tuttle, Absurdly Expensive EpiPens Are Driving Families to Dangerous
Lengths, TIME MAGAZINE, July 7, 2016,
http://time.com/money/4396467/epipen-prices-altemative/.
' Anna Davies, Parents Are Getting Screwed by the Cost ofEpipens, NEW YORK POST,
Aug. 22, 2016, https://nypost.com/2016/08/22/parents-are-getting-screwed-by-the-cost-
of-epipens/.
'Brendan Pierson, Mylan Hit with New Class Action Lawsuit over EpiPen Pricing,
REUTERS, April 3, 2017, https://www.reuters.com/article/us-mylan-nl-epipen-
lawsuit/mylan-hit-with-new-class-action-lawsuit-over-epipen-pricing-idUSKBN1752CA.
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consumers will simply purchase another generic product. A platform that has
these characteristics allows consumers to speak directly to manufacturers (a
feature which is not present in litigation) and to show that this group of
consumers dictates the demand for this product, and they have immense buyer
power over Mylan. The communication and open sharing of information is not
present in litigation, and this is how the class of consumers can create and
leverage buyer power in alternative dispute resolution processes to cause
effective change in the healthcare industry.
This article begins with the many theories, method, and real-world
examples of how prescriptions drugs are priced. The second closely examines
Mylan's EpiPen and other epinephrine devices. The third section outlines the
requirements of class action litigation and how alternative dispute resolution
can seamlessly enter the process and provide a mutually-beneficial settlement.
The last section concludes that alternative dispute resolution is a more
economical and productive solution for all parties involved in Mylan's price-
setting of the EpiPen.
II. THE COMPLEX BACKGROUND OF PREsCRIPTION DRUG PRICING
Participants within the healthcare system must concede that
pharmaceutical companies are necessary in our modern world. Without
pharmaceutical companies shouldering the immense costs of research and
development of drugs and other technologies, many individuals would be at a
loss for quality healthcare. Creating, testing, and following through the
approval process is long and expensive, likely only feasible for organizations
with large amounts of resources.6 To incentivize the progress of modern
medicine, the price of the prescriptions must cover at least the marginal' cost
of production. Utilizing ADR in this class action is not meant to de-emphasize
the role of manufacturers, but rather to find more long-term ways to reduce
costs and protect benefits within society.
The values, and price tags of prescription drugs are compilations of
different measures. The EpiPen is specifically ascribed value due to its unique
design, lack of availability, and immense benefits. Consumers may not
recognize the characteristics of the EpiPen that contributed to the price
6 It costs nearly $3 billion to develop, approve, and bring a drug to market. See Rick
Mullin, Tufts Study Finds Big Rise In Cost Of Drug Development, Pharmaceuticals:
Benchmark report sees the cost of bringing a drug to market approaching $3 billion,
CHEMICAL & ENGINEERING NEws, Nov. 20, 2014,
https://cen.acs.org/articles/92/web/2014/1 1/Tufts-Study-Finds-Big-Rise.html.
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increase; ADR will open communication between a class of consumers and
the manufacture to explain the present interests for production and sale of the
product.
A. Ascribing Value to Pharmaceutical Drugs
Prescription medications are products of science, industry, and
progress. But they are also deeply personal, human, and linked to enigmatic
societal values. As the human population is living longer and healthier lives,
prescriptions drugs are a part of a normalized human experience. A study by
the Mayo Clinic found seventy percent of Americans take at least one
prescription drug, and twenty percent of the population are on at least five
prescription medications. 8 Clearly, consumers need and want these
prescription drugs.
Prescription drugs are part of a normal, modem, healthcare regimen.
Therefore discussion on the societal value and the related price tag of
pharmaceuticals must be included in this article.
One theory of drug pricing reflects the advantages the product
contributes to society known as the value-based pricing method.9 Following
this method, if a prescription drug provides a large value, society should be
willing to pay a higher price.10 For example, because Mylan's EpiPen
provides a large value in saving lives for so many people with so many
allergies; the value-based method asserts consumers should be willing to pay
the large amount Mylan has set. Value-pricing is an accepted standard in the
healthcare industry along with the trend of value-based insurance design. This
insurance design is founded on the ideal that consumers are willing to pay for
quality over quantity within the medical care field." Whether or not patients
are willing to spend more for high-quality services is of little import as health
issues and needs arise, the consumer will pay whatever price is necessary to
obtain care.12 Both these theories indicate that consumers understand that the
' Healthy Living, Prescription Drugs: 7 Out Of 10 Americans Take At Least One,
Study Finds, THE HUFFINGTON POST, Jun. 20, 2013.
' Richard Manning, The Role of Value And Cost in Prescription Drug Pricing,
LAw360, (Sept. 27, 2016, 12:36 PM), https://www.1aw360.com/articles/845069.
10 d
" Robert Rubin, Value Pricing for Drugs: Whose Value, What Price?, HEALTH
AFFAIRS BLOG, Mar. 28, 2016, http://healthaffairs.org/blog/2016/03/28/value-pricing-for-
drugs-whose-value-what-price/.
12 Morgan A. Muir et. al., Clarifying Costs: Can Increased Price Transparency
Reduce Healthcare Spending?, 4 WM. & MARY POLY REV. 319, 320 (2013) (stating price
demand within the healthcare industry is uniquely inelastic, as consumers will pay
regardless of quality when a condition becomes serious).
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dollar amount of the price sticker is about more than just the consumer's
money-it is about knowing they will receive a necessary and meaningful
value.
Price-setting values are complicated, however, by the myriad of
conflicting values held by the many stakeholders in this industry. Consumers,
as described, determine value by the benefits provided. But manufacturers and
suppliers also consider a "novelty multiplier, the cost of development, a rarity
multiplier, and the population burden of disease" which the prescription drug
aims to treat." If a drug is especially hard to develop and is especially novel,
manufacturers are likely to say these characteristics necessitates a high price
tag." And because there are few checks and limitations to the price-setting of
pharmaceuticals, the high value leads to high cost without a determination of
any affordability benchmark."
Pharmaceutical drugs can be measure and priced by the value
providing to society.16 An essential value is present when a drug is necessary
to many people, and it might be unfair to price the drug following value and
above the affordability benchmark. This is the scenario currently happening
with the EpiPen;17 a life-saving drug delivery device that is necessary for an
expanding set of the population and is becoming more out of reach of the
population as the price increases. Fifteen million Americans have food
allergies, and food allergies among children have increased by fifty percent
between 1997 and 2011.1" The segment of the population searching for
specific life-saving drugs is growing, and it is becoming more unethical to
strictly follow the value-based method in setting high prices that make the
product inaccessible for the consumers that need it most.
13 Robert Rubin, Value Pricing for Drugs: Whose Value, What Price?, HEALTH
AFFAIRS BLOG (Mar. 28, 2016), http://healthaffairs.org/blog/2016/03/28/value-pricing-
for-drugs-whose-value-what-price/.
14 d
" Isaac D. Buck, The Cost of High Prices: Embedding an Ethic of Expense into the
Standard of Care, 58 B.C. L. REv. 102, 123 (2017) (stating the high costs of healthcare is
affected by overpriced pharmaceutical drugs and a regulatory system that allows
pharmaceutical companies to charge prices in order to seek greater profits).
" Rubin, supra note 13. The ethical dilemma arises when the price of a drug is high,
and the value provided by the drug is similarly high.
" Mylan's EpiPen is not the only drug that has experienced rapid and exponential
price hikes, for a discussion regarding Martin Shkreli's 5000% price increase on Daraprim
(a prescription used to treat HIV) see Isaac D. Buck, The Cost offHigh Prices: Embedding
An Ethic ofExpense into the Standard of Care, 58 B.C. L. REv 103,117-18 (2017).
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B. Marketplace Pricing ofPharmaceutical Drugs
Pharmaceutical companies have a large role and the greatest influence
over setting the prices of prescription drugs. Even the federal government-
the largest purchaser of prescription drugs-has no role in negotiations when
buying drugs for Medicare. 19 Like the common consumer, the federal
government is simply a "price-taker" and must accept he price set out by the
drug companies.2 0 It seems intuitive that a group that procures so much of the
product should have greater buyer power, which could (and should) be
leveraged against the manufacturers. But there is simply no opportunity for
the federal government to exercise this buyer power.
In each section of Medicare, drugs are priced using different criteria
and different processes. Medicare Part B regulates physician visits and similar
non-hospital services; in this section drug pricing utilizes retroactive data to
set future prices.21 Prescription drug companies review the prices of drugs
administered in doctor's offices by determining the average sale price of the
drug from the previous quarter, and uses that to set a corresponding price for
the prescription drug in the current quarter.22 If the data shows physicians
were charging a high price for the drug in the previous quarter, the price is
likely to stay high or trend higher to cover rising costs of development.2 3
While physicians are not setting the price for the prescriptions they prescribe
within their clinics and hospitals (the prices are set by the manufacturers), the
amount of prescriptions filled provides an indication to the manufacturer that
consumers are willing to pay the retroactive price and future prices can be set
accordingly.
" John B. Kirkwood, Buyer Power and Healthcare Prices, 91 WASH. L. REV. 253,
262 (2016).
20 Id See also EZEKIEL J. EMANUEL, REINVENTING AMERICAN HEALTH CARE 220
(2014) ("Substantial research has shown that the prices paid for health care services in the
United States are high.").
2 Kirkwood, supra note 19, at 262.22 Id See also Jeanne Whalen, Why the U.S. Pays More than Other Countries for
Drugs: Norway and Other State-Run Health Systems Drive Hard Bargains, and Are
Willing to Say No to Costly Therapy, WALL ST. J. (Dec. 1, 2015) (comparing the
pharmaceutical pricing scheme in Norway (which includes negotiation between
manufacturers and consumers) to the United States' price setting in Medicare Part B based
solely on historical prices).
23 Brendan Murphy, Getting High on Profits: An Analysis of Current State and
Federal Proposals to Rein in Soaring Drug Prices, 12 J. HEALTH & BIOMED. L. 37, 42
(discussing that patents are important to protect because there are high costs of investment
and the development can be easily replicated by competitors).
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Under Medicare Part B, pharmaceutical companies and private
prescription drug plans (PDPs) negotiate with each other to set prices of the
prescription drugs.24 These are the only two parties allowed in the negotiation
process, notably excluding the federal government. PDPs are able to wield
their own buyer power over drug manufacturers and obtain discounts.
Primarily, PDPs seek to lower prescription drug prices by promising to bring
additional business to the pharmaceutical company.25
PDPs are most successful in negotiating prices with brand-name
prescriptions for which there are at least a few close substitutes, or generic
prescriptions.26 Because the PDPs have other options to provide similar
prescriptions to consumers, and the manufacturer knows this, the PDP has
buyer power and the manufacturer will respond to negotiations to keep the
PDPs' business.
PDPs utilize a formulary: a tiered list of the prescription drugs the plan
covers which affects what prescriptions the consumer is mostly likely to
purchase.27 The tier a certain drug is on dictates how often a physician will
prescribe that drug to patients, because of the amount of coverage the PDP
provides that drug. The tier indicates how much of the cost of the drug the
PDP will cover, affecting how much a consumer will have to pay out of
pocket.2 8
PDPs negotiate with drug manufacturers by removing, adding, or
altering the tier of prescription drugs on the list. If the PDP can show adding
the specific drug to the formulary will increase the pharmaceutical
manufacturer's business, the manufacturer is likely to accept the deal that
involves a lower price.29 If the prescription drug is already on the formulary,
the PDP will negotiate that moving the drug to a different tier that offers lower
co-pays, will lead to greater sales of the product.30 Therefore, even though the
drug may be priced lower than the manufacturer's optimal price, this tier
placement will encourage more purchasing and profit to the manufacturer.
24 Kirkwood, supra note 19.
2 5Id at 263. See also Lee B. Staley, A Drug's Worth: Why Federal Law Makes It
Hard to Pay for Pharmaceutical Performance, 98 B.U. L. REv. 303, 317 (2018) (under
Medicare Part D, PDPs negotiate with pharmaceutical manufacturers regarding the amount
of access the company has to the health care providers' formularies, and how many
consumers will then have access to the drug).
26 Kirkwood, supra note 19, at 264.
27 Id.
28 Id (placement on the formulary dictates the amount of copay, and drugs with lower
copay lead to greater consumer sales).
29 Kirkwood, supra note 19, at 264.
30 Id. at 265.
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As demonstrated in the negotiations between PDP and manufacturers;
harnessing buyer power and demonstrating that lower prices will amount to
sales can lead to successful negotiations for prescription drug consumers and
pharmaceutical manufacturers alike.31 This negotiation model under Part D is
a satisfactory model for future interactions with other consumers. Allowing
the average consumer to prove to manufacturers that lower prices encourage
consumer purchase (like PDPs have done) creates buyer power for the class
action plaintiffs in an ADR process.
Now looking at the manufacturer perspective, pharmaceutical
companies justify high prices of prescription drugs because of the high prices
of research and development.32 Before the prescription drug reaches the
consumer, the manufacturer shoulders the complex operation of scientific
discovery and bureaucratic red tape. After completing intense and long-term
research and development, a drug must pass clinical trials and receive approval
from the Food and Drug Administration which can cost on average between
five and a half billion dollars to almost six billion dollars;33 additionally, there
are a number of middlemen that must also receive compensation for their
work.34 For example, a distributor receives the drug from the manufacturer
and charges a fee, then sells the drug to a pharmacy which receives its own
fee.35 All these fees must be satisfied in the sticker price on that drug. A
consumer is not simply paying for the drug or drug delivery device, but also
for these many processes. From scientific research to prescription pick-up,
pharmaceuticals are an expensive business. These processes are essential,
though, and must be incentivized so drug manufacturers continue the
expensive methods of creating drugs with a proportionate price for the
protection and benefit of society.
However, the price must also reflect the demand, need, and value from
the consumer's perspective. Though the processes to put a drug on the
marketplace are expensive, the price cannot be so exorbitant that those who
need the drug cannot access it. An alternative dispute resolution process is
more suitable to protect these costs and interests of the many parties, as drug
manufacturers and consumers can explain these interests and create more
3 Kirkwood, supra note 19, at 266.
32 Murphy, supra note 23, at 65.
3 Id See supra note 6 (past studies show it can also cost up to $3 billion dollars to
bring a drug to market).
34 Katie Thomas, The Complex Math Behind Spiraling Prescription Drug Prices, N.
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flexible solutions through a process that is not as adversarial and positional as
litigation.
III. MYLAN AND ITS PROFITABLE DRUG DELIVERY DEVICE
In order to understand how Mylan has become a large player within the
pharmaceutical industry, some discussion on the history of the corporation is
necessary. Mylan first came into existence in 1961, distributing medical and
health products to medical professionals with the goal of providing access to
affordable medicine.3 6 Mylan has now grown into a company with more than
7,500 different products.3 7 One of their products is the EpiPen, a self-
injectable, epinephrine device."'
A. The Innovative EpiPen
Epinephrine is the first line treatment for a person that comes into
contact with a life-threatening allergen and begins experiencing anaphylaxis.39
Anaphylaxis is a common allergic response causing a spectrum of reactions
from a rash, to a more immediate and harmful swelling of the throat that
restricts breathing. 40 Specifically, for individuals with life-threatening
allergies, the EpiPen is used before any other medical treatment to save their
life. Many individuals have minutes after contact with the allergen before all
breathing is restricted-usually not enough time for medical personnel to
arrive and provide a dosage of epinephrine. 41 What makes Mylan's
prescription drug so valuable is not only the life-saving-yet miniscule-dose
of epinephrine,4 2 but also the delivery device of the needle in the EpiPen.43
This substantial, large needle is able to pierce through clothing quickly and
36 See generally, EPIPEN, https://www.epipen.com/en/about-epipen (last visited Apr.
20, 2018),
3 See generally, Mylan, Global & U.S. Fact Sheets,
https://s3.amazonaws.com/filecache.drivetheweb.com/mr5mr ylan/177540/20170627
Mylan%20Global%20and%20US%2OFact%20Sheet.pdf (last visited Apr. 20, 2018).
38 See generally, Mylan, http://www.mylan.com/en/products (last visited Apr. 20,
2018).
" EPIPEN, https://www.epipen.com/en/ (last visited Apr. 20, 2018).
40 MAYO CLINIC, Anaphylaxis, https://www.mayoclinic.org/diseases-
conditions/anaphylaxis/symptoms-causes/syc-20351468 (last visited Apr. 20).
41 MAYO CLINIC, Anaphylaxis, https://www.mayoclinic.org/diseases-
conditions/anaphylaxis/diagnosis-treatment/drc-20351474 (last visited Apr. 20).
42 EPIPEN, https://www.epipen.com/en/about-epipen-and-generic/what-is-
epinephrine (last visited Apr. 20, 2018).
43 EPIPEN, http://www.epipen.co.uk/hcp/faqs/ (last visited Apr. 20, 2018).
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can easily be administered by the person in anaphylaxis themselves, which is
necessary as the EpiPen is designed for emergency situations." This specific
drug delivery device is what makes this drug so remarkable and so effective
for consumers.
EpiPens have been in the marketplace since 1977, and Mylan first
acquired this drug delivery system in 2007.45 In 2007, the EpiPen cost fifty-
seven dollars and the price has since risen to five hundred dollars or more.4
In 2015, due to creative advertising and this price increase, EpiPen profits
constituted forty percent of Mylan's total operating profits.47 Though Mylan
creates and sells over 1,000 products, this one drug constitutes almost half of
the entire corporation's profits. Over these years, Mylan has not made
significant changes or improvements in the drug or the drug delivery device,
but has instead focused its efforts on massive campaigns to increase
anaphylaxis awareness and preparedness. 48 Mylan fostered demand by
partnering with organizations and businesses to stock EpiPens in schools and
public places (like Disney theme parks and cruise ships).4 9 Additionally,
forty-seven states now encourage or require schools to stock EpiPens.so
Additionally, manufacturers and physicians suggest people with life-
threatening allergies carry two doses of epinephrine (two Epipens) with them
at all times, if the person does not respond to the first dose or if it is incorrectly
injected."
B. The Threat of Generic Epinephrine Devices
For those with life-threatening allergies and organizations required by
law to stock EpiPens, purchasing an EpiPen is not optional and they are forced
to purchase at the new high costs. However, with recent media attention there
have been more efforts to create a generic and less expensive epinephrine
EPIPEN, http://www.epipen.co.uk/hcp/faqs/ (last visited Apr. 20, 2018).
4 Emily Willingham, Why did Mylan Hike EpiPen Prices 400%? Because They





48 Cynthia Koons & Robert Langreth, How EpiPen Became a Hit, BLOOMBERG
BUSINESSWEEK, Sept. 28, 2015, at 21.
49 Id
50Id.
s Id. See also United Press International, Allergic to Food: Carry Two EpiPens, (Mar.
26, 2010) https://www.upi.com/Allergic-to-food-Carry-two-EpiPens/28851269659469/.
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delivery device.5 2 Consumers need to purchase epinephrine devices and if
Mylan does not engage with the consumers to understand how the high price
is hindering access, these consumers will purchase the drug elsewhere." This
provides consumers buyer power to negotiate with Mylan to lower prices,
making alternative dispute resolution tactics an accessible path for a solution.
Unlike litigation where the scope is only Mylan's actions, parties can discuss
the presence of generic epinephrine prescriptions and how that will diminish
Mylan's market.
IV. ADR IN CLASS ACTION LAWSUITS MODEL SOLUTIONS TO THE
PHARMACEUTICAL INDUSTRY
Pharmaceutical companies, as the cost-bearer of production, view the
value of the drug as including the work, time, effort, and creativity that went
into development. However, the prescription-taker is more likely to see the
human value as more important than the costs of bring the drug to market.
Both values play into how prescription drugs should be priced, and it is only
through alternative dispute resolution in which both interests are presented that
both sides can find solutions. Litigation will not uncover these interests, or
search for a way to find a mutually beneficial solution. Alternative dispute
resolution methods focus on the conflicting and overlapping interests of the
parties, providing an ample opportunity for consumers to amass buyer power
(especially within a class action lawsuit), and having the opportunity for
consumers to speak with the manufacturer about how they create the demand
for the product and not have other generic options that will detract from
Mylan's profits. A class action already provides the average consumer more
buyer power, and ADR will capitalize on negotiation techniques to seek a
lower price for the prescription medication.
Class actions are incredibly powerful vehicles to bring attention to
large societal issues like racial discrimination or to achieve large-scale
progress like prison reform or ending consumer fraud.54 Many claims are
likely to not be brought or see reward if pursued on an individual claim basis
52 Nathan Bomey, CVS Targets EpiPen with Cheaper, Generic Version, USA TODAY,
Jan. 12, 2017, http://www.usatoday.com/story/money/2017/01/12/cvs-health-mylan-
epipen-injector-impax-adrenaclick-donald-trump/96479776/.
" Id. (CVS offering a generic-and less expensive-version of the EpiPen will draw
more consumers away from Mylan and allow other consumers to purchase epinephrine
devices that previously could not afford Mylan's device).
54 See Jean R. Stemlight, As Mandatory Binding Arbitration Meets the Class Action,
Will the Class Action Survive?, 42 WM. & MARY L. REv. 1, 31 (2000).
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but must be brought as a class action to see real action and resolution."
Whether a class action is pursued in litigation or alternative dispute resolution,
the procedure remains similar. The difference lies in the process in achieving
a mutually-beneficial outcome. ADR empowers the parties to create their own
solution, affords each party opportunity to communicate, and come to an
agreement that is unique. A judge may not be able to rule in a way that sets
standards for future price-setting practices, but ADR combines a class of
consumers to prove they have power and can create future change for the
industry.
A. The Use ofADR in Class Action Lawsuits
Just as a class action lawsuit begins, the members of the class must
meet the requirements of Federal Rule of Civil Procedure Rule 23(a) and
23(b).5 6 Rule 23(a) requires the party show the class is numerous, the
questions of law or fact are common to the class, the claims are typical of the
claim of the class, and the representative parties will fairly and adequately
protect the interest of the class. 5 Additionally, Federal Rule of Civil
Procedure Rule 23(b) requires the class show that it would be incompatible for
the individual plaintiffs to bring this claim themselves." This can be satisfied
where a unitary decision is appropriate to all the plaintiffs as they have
suffered a similar harm.5 9 The plaintiffs in this class action are likely to
receive the necessary class certification as they have all suffered the same
harm from the singular action of Mylan's expensive pricing of EpiPens. One
decision, or agreement, regarding this claim is sufficient to resolve the issues
throughout the class and the certification process can continue.
Though class actions are frequently utilized only in the litigation
perspective, many jurisdictions require the parties attempt to resolve the
dispute before it enters the courtroom.60 This court-ordered ADR can uncover
and define facts, complexities within the case, overlapping issues, and then
quantify the possible value of the claims so when the case comes to litigation
it is more simple for a judge to rule.61 Other scenarios of court-ordered ADR
ss1d at 80.
See Fed. R. Civ. P. 23(a)-b).
" Fed. R. Civ. P. 23(a).
58 Fed. R. Civ. P. 23(b).
" Myron S. Greenberg & Megan A. Blazina, What Mediators Need to Know about
Class Actions: A Basic Primer, 27 HAMLINE L. REv. 191, 205-06 (2004).
' See Fed. R. Civ. P. 23(a); See also Corby Pelto, ADR: Building Bridges in Mass
Tort Claims, 57 DisP. RESOL. J. 10, 12 (2002).
61 Id at 12.
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require the parties to utilize arbitration to not only clarify issues, but also to
reach a settlement.62 However, when the ADR process is mandated by the
court, it is expected that there will be a high amount of supervision and
cooperation between the parties, neutrals, and the court.63 This creates many
logistical concerns as the court will generate inefficiencies and remove
flexibility for the parties.'
Once the claim is filed, a party to a class action need not wait to be
ordered to utilize ADR but instead can elect to participate in a private and
voluntary mediation which allows the parties to more effectively reach an
agreement without entering a courtroom.65 One of the main benefits of a
private mediation is the choice parties have over who will function as their
third-party neutral.' If the case encompasses a specific or complicated
subject-like healthcare-it would be beneficial to invite a neutral that has
expertise in the area. Rather than rely on ajudge with general legal knowledge
or be assigned a neutral that may not understand the industry, parties can
choose a neutral that is knowledgeable and will assist in generating realistic
options for settlement. With all the parties and neutrals empowered to act and
equipped with correct knowledge, they can be more proactive, flexible, and
creative as there is no court supervision orjudge controlling the process.
Whether the ADR process is court-mandated or voluntary, any
proposed class action settlement is subject to court approval.67 The court is
the guardian of the class and must ensure the settlement is fair to all members,
and not just the representatives of the class.68 Class members must be notified
of the proposed agreement and given opportunity to object.69 Once approved,
the parties have a mutually-beneficial solution to which they have both
contributed.
62 Id. A judge can require the parties to reach a settlement through a "mini-version of
the case" or utilizing a less formal settlement discussion process.
63 Greenberg & Blazina, supra note 59, at 214.
4 Sternlight, supra note 54, at 51.
65 Id at 52-53.
66 Id at 27.
6' Greenberg & Blazina, supra note 59, at 217.
61 Id at 218; See Ortiz v. Fibreboard Corp., 527 U.S. 815, 864-65 (1999) (rejecting
the class action settlement proposal because it did not adequately meet the needs of many
of the members of the class); Amchem Prods Inc. v. Windsor, 521 U.S. 591, 609 (1997)
(holding that a class action may be formed for settlement purposes only, but still must meet
the requirement of Federal Rule of Civil Procedure 23).
69 Greenberg & Blazina, supra note 59, at 219.
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1. LEVERAGING BUYER POWER IN ALTERNATIVE DISPUTE
RESOLUTION
In order to find an efficient, longstanding solution to the high price of
EpiPens, the plaintiffs in the class action suit against Mylan must create,
aggregate, and leverage their buyer power. These consumers can do this by
demonstrating they have demand for the product, options to buy the drug
elsewhere if Mylan does not participate and this all will truly affect Mylan's
profits.
Class action litigation and utilizing alternative dispute resolution in
said class action fulfills the right of health care consumers to a fair and efficient
process for esolving differences in their health care services.70 In this modern
age of health care service, consumers are becoming more involved in their
health care decisions and controlling how they receive care. However, there
are likely to be differences in the desires of consumers and providers giving
rise to convoluted disputes. A national study conducted by the American Bar.
Association examined how creative processes (like alternative dispute
resolution) were already working within the health care sector and whether it,
leads to satisfactory and imaginative solutions.7' The study found that
alternative dispute resolution is a useful resource as it relies on non-adversarial
techniques, and aids to preserve partnerships between both parties in health
plan-consumer disputes.72 Preserving relationships between providers and
consumers in the healthcare industry is necessary. If patients begin to distrust
and avoid services, physicians, hospitals, and pharmaceutical companies will
all suffer. An adversarial process can exacerbate the different positions instead
of working to bridge gaps and mend relationships as dispute resolution
processes eek to fulfill.
A drawn-out a vicious litigation process will create negative attention,
and push target consumers away from supporting Mylan. Without the
consumers, there is no demand for the product and Mylan will lose business
from its drug that provides almost half of its profits." Mylan needs to maintain
a consumer base, especially as their competitors are planning to release a
similar drug delivery device for a much lower price.74 A class action suit poses
70 Naomi Karp & Erica Wood, Medispute: Resolving Health Care Conflicts: Health
Plan Internal Consumer Dispute Resolution Practices: Highlights from A National Study,
5 J. HEALTH CARE L. & POL'Y 283, 286 (2002).
71 Id at 294-95.
72 Id at 323.
73 Willingham, supra note 45.
7 Matthew Herper, In Rube Goldberg Price Scheme, EpiPen Competitor Auvi-Q to
Be Free for Patients, $4,500 for Their Insurers, FORBES (Jan. 19, 2017, 12:02 PM),
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unique problems to the defendant, which can be capitalized by the plaintiffs in
reaching a more satisfactory agreement. The defendant usually has an
increased exposure to liability, as there is a concern over the media coverage
and resulting public image, stockholder relations, or stock valuation.75 This
certainly happened to Mylan as its stock trading was traded at historically low
valuations right before their Congressional hearing regarding the high price
setting.76 Unlike the plaintiffs, the defendant has large concerns about public
image and ensuring a profit margin. By leveraging this weakness, and the
already looming media coverage, the plaintiffs in the class action have an
opportunity to force Mylan to engage and create an action that will better the
corporate image.
Mylan has much to lose in this lawsuit process. This class action
attacks the pricing scheme of the product that keeps the company successful.
And a product that many people know, recognize, need, and value. The
consumers in this class action, however, have very little to lose in pursuing a
claim against Mylan. If Mylan does not cooperate, the consumer will buy
CVS' new generic epinephrine device (or any number of generic prescriptions
being created) and will not be subsequently harmed. Additionally, the class
of consumers will not be harmed by media attention but will likely find support
and be emboldened by other similarly-situated consumers throughout the
county that are not a part of the class.
The consumers face numerous benefits in electing to participate in an
alternative dispute resolution method, but Mylan can also benefit as it can
temper much of the negative press Mylan has received. And ADR can
possibly create positive attention if Mylan does work with the class of
consumers to institute an option to provide inexpensive EpiPens, and this will




7 Greenberg & Blazina, supra note 59, at 203.
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2. LEVERAGING PERSONAL AND POLICY ARGUMENTS IN
ALTERNATIVE DISPUTE RESOLUTION
Healthcare presents unique complications as the core of the industry
concerns decision involving life and death. " The industry relies on
relationships between providers and consumers of healthcare, pharmaceutical
companies, and medical device companies to enhance individuals' well-
being.7 8 Though all these players in the healthcare system need the other to
survive and be successful, the varied interests often lead to a deeply entrenched
positional, adversarial environment which alternative dispute resolution may
be able to break down.79 Traditional class action litigation, conversely, can
foster the spectrum of positions and create greater divide in all the
relationships.
With such a complex and emotional topic, alternative dispute
resolution's goals of defining underlying facts in the dispute can address
complicated issues that would otherwise be too polarizing to confront."
Instead of focusing on the positions these players hold-as in a traditional.
litigation process-alternative dispute resolution anchors solutions to the
interests of the parties. Since this dispute revolves around access to life-saving
medication, interests-especially for the plaintiff consumers-may not be
rational and alternative dispute resolution can aid in breaking down this
perspective to manageable, actionable interests.
ADR will help go beyond the positions and portray the emotional.
values in a way that can be understood by all parties. Neutrals can frame the
plaintiffs' interest-their need to buy the lifesaving drug in numerous
quantities and annually-as a method that will provide Mylan a steady stream
of profit. Instead of focusing on one individual's allergy and need to
inexpensively purchase an EpiPen, broadening the scope to show that a large
population has deeply personal reasons to obtain this product will be a more
powerful negotiation tactic. Just as PDPs negotiate with manufacturers to
show a lower price will actually increase profit, an ADR neutral can analyze
the consumer's emotional interests as incentives for Mylan to change its price-
setting practices. A litigation process does not present an opportunity for the
class of consumers to capitalize on this policy argument, as a judge must rule
according to other questions of law. Since ADR does not only focus on the
n Carrie Menkel-Meadow, Scaling Up Deliberative Democracy as Dispute




8o Greenberg & Blazina, supra note 59, at 212.
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legal claims of each party, the consumers have more liberty to explain to
Mylan their personal needs, and how that creates the demand for this product.
B. Possible Hindrances in Utilizing ADR in Class Action
Lawsuits
As is the case with working in any large group of people, maintaining
common goals and responsibilities is difficult in class action lawsuits." Any
relief sought must be acceptable both on an individual plaintiff basis and
appropriate class wide,8 2 and it is the court's responsibility to ensure that any
proposed agreement provides a real and tangible benefit to class members."
This requirement may be problematic when utilizing negotiation practices and
seeking more creative solutions to reduce the cost of the pharmaceutical for
the class of plaintiffs. A creative solution to the price gouging of the EpiPen
may not be quantifiable and therefore difficult for a court to evaluate. A
settlement may not create present recovery for the class in terms of monetary
damage, but a more efficient ADR settlement can promise future benefits in a
lower price of the EpiPen.
Along the same vein, a large group of plaintiffs increases the
likelihood of the presence of "bad-seeds" within the process.' This term is
simply used to describe difficult people within the class that may hamper the
success of reaching an agreement for the larger group;" bad-seeds could be
hold-outs that will only accept a specific settlement, or an individual who truly
believes that there are better options to be found.
Facilitators, mediators, and counsel must be aware of this risk within
the group and learn how to combat and smooth the divides that are inevitable.
This issue can be circumvented, but not without preparation." Facilitators
within the dispute resolution process can recognize the strongly held views
and emotions of the difficult persons by involving them into more principled
negotiations and claims?. For example, mediators can work with these bad-
seeds in smaller groups and attempt to disarm them by encouraging a more
81 Id at 205.
82Id
83 d. at 217.
" Menkel-Meadow, supra note 77, at 25.
8 Id.
' See generally, e.g., DOUGLAS STONE ET AL., DIFFICULT CONVERSATIONS: How To
Discuss WHAT MATTERS MOST (2000).
17 Menkel-Meadow, supra note 77, at 28.
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positive future process. 8 By working with these plaintiff members
individually, divide or destruction within the class can be prevented.
Overall, the possible hindrances in utilizing alternative dispute
resolution require more attention, time, and emotional energy. Not only must
the plaintiff class attend to the conflicting interests of Mylan, but also the
possible conflicting interests within their own group. However, the issues
presented in utilizing alternative dispute resolution in this class action are not
unique. The possibility of divide, conflicting interests, and procedural
requirements of seeking court approval exist within all class action lawsuits.
Therefore, because these problems are not unique, facilitators and mediators
and counsel can be adequately prepared on how to handle the problems. A
class actidn suit against a large pharmaceutical company does not present
unsurmountable issues, and the ability to reach a beneficial and effective
solution is probable despite the extra labor that it may require.
Though most class actions do not utilize alternative dispute resolution,
the impediments in this process are uncommon and the benefits provided by
ADR greatly outweigh the costs.
1. MEDIATION PROMOTES CREATIVTY, BUT ENABLES
BREAKDOWN
Mediation is the use of a disinterested third party to assist the parties
in reaching a voluntary settlement between parties.89 A mediator, also called
a neutral, assists the members of the party through a joint decisionmaking
process."0 Due to the informal and non-binding nature of the mediation
process, it generally allows for more honesty and creativity in reaching a
solution that is amenable to all disputants.1 Those involved in mediation are
more likely to support and stay true to the agreement as they have an emotional
and mental commitment to the creation.92 Mediation, rather than other forms
of alternative dispute resolution and litigation, is more likely to be used when
both parties believe there is a possibility of a future relationship.9 3
The conflict between the class of plaintiffs and Mylan is highly
emotional and in need of a creative process to find a more permanent solution
to the unconscionable pricing of the EpiPen. Having a designated neutral party
involved within the decisionmaking process allows the affected consumers to
" Menkel-Meadow, supra note 77, at 25.
89 Greenberg & Blazina, supra note 59, at 212.
90 d.
91 Id
92 Id at 213.
93d
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air the emotional effects of the high pricing. And if Mylan can respond to the
underlying interests of the emotional reaction as interpreted by a neutral party
in mediation, they can maintain this group of consumers.
Mylan may be more likely to engage in a mediation rather than
litigation or another alternative dispute method because of its non-binding
nature. This allows both parties to seek inventive options to lower the price
of EpiPens and make them more accessible to consumers. With the knowledge
that the company will not be forced to complete any one agreement, the Mylan
representatives are more likely to be candid and be inventive. This allows the
plaintiffs to gather more information about Mylan, and their pricing process.
Any information garnered through the mediation can be leveraged towards
more buyer power against the pharmaceutical company.
Another benefit of utilizing mediation is the mediator does not have
an evaluative role. The mediator's purpose in the process is to facilitate
communication, clarify interests, and assist in creating options.94 The parties,
rather than the mediator, will be challenged to work with each other to find an
agreement. A possible solution which may be created in mediation is a process
requiring Mylan to acknowledge the consumer perspective in setting the
EpiPen price. Perhaps this could include the manufacturer consulting and
seeking approval from certain consumer representatives, or creating a survey
outlining quantifiable information demonstrating what consumers are willing
to pay for this product. A judge in a traditional litigation setting could not
make a ruling that incorporates these unique, creative, and forward-thinking
options.
Though mediation is the ADR method that promotes the most
creativity, the mediator has no duty to ensure a settlement is reached and
therefore the parties have sole responsibility for negotiating a final agreement.
If either side cannot agree to an option or cannot move past one issue, the
entire process will break down and the parties will leave the table. Due to the
inherently complex nature of a class action-the many individuals with many
views and desires-arbitration, rather than mediation is the best option for the
class and Mylan to reach an agreement.
274
9 4 See Greenberg & Blazina, supra note 59, at 212 (discussing how advocates argue
that the mediation process enables parties to engage in a more user-friendly method for
reaching a satisfying resolution).
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2. ARBITRATION PROVIDES STABILITY, RELIANCE, AND
FLEXIBILITY
Usually when mediation has proved unsuccessful, parties turn to
arbitration where the neutral provides a decision after hearing arguments and
evidence from both sides.95 This decision can be binding and is left to the
neutrals to formulate the agreement.96 Unlike in mediation where the neutral
is an active participant guiding and facilitating discussion between the two
parties, the neutral in arbitration is passive and allows the disputants to
command the conversation." What arbitration lacks in creativity is made up
for in the expediency of decisions; similar to traditional litigation without the
costs and more flexibility. 9 8
Arbitration can be useful in this class action because the situation is
so convoluted. Involving a decisionmaker that is neutral and available to hear
large amounts of information is an incentive to both parties involved. Mylan
can discuss with the neutral the rationale of the pricing of EpiPen, which
includes the research, development, unique design, and value it provides to
consumers. Moreover, the neutral can learn how and why it is so important to
the pharmaceutical company to continue receiving high profits from this
product.
Likewise, the plaintiffs have ample opportunity to present their
interests in purchasing EpiPens at a lower price. Arbitration allows consumers
to exercise greater buyer power that normally is not available within the health
care industry. In this ADR process, the plaintiffs need only convince one
neutral individual rather than sway the opinion of the party holding the
monopoly (unlike discussing this claim with only Mylan in mediation). The
neutral decisionmaker, unlike Mylan, may be more likely to hear the emotional
arguments of the consumers since their access to Mylan's product represents
a true life or death decision in many cases.
Arbitration also allows for some distance between the parties that may
prevent any further damage to the relationship.99 This creates formality and
stability that is usually only found in litigation proceedings. Knowing and
understanding that the final agreement was created by a person who heard,
9 Greenberg & Blazina, supra note 59, at 212.
* See John W. Cooley, MEDIATION ADVOCACY 9 (1996); Greenberg & Blazina, supra
note 59, at 213 (when an arbitration is binding, the decision is binding and enforceable.
Conversely, nonbinding decisions are advisory only).
9 Greenberg & Blazina, supra note 59, at 213; see also John W. Cooley, MEDIATION
ADVOCACY 9 (1996).
98 Greenberg & Blazina, supra note 59, at 213.
9 See Id.
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analyzed, weighed both arguments will provide a greater sense of justice to
the parties. This is similar to litigation, but the arbitrator has more flexibility
on the solution rather than just handing down a decision.
Though an arbitrator may not propose an agreement hat incorporates
the creative solution mentioned previously, whatever agreement is reached can
be binding. The future actions or process decided upon will control the
relationship between Mylan and the class, provide consumer protection while
balancing the economics interests of the company. Again, this provides a
similar sense of security and justice as litigation but in a more efficient and
cost-effective manner.
Alternative dispute resolution processes, allows this specific class of
plaintiffs more interaction and communication with a pharmaceutical
company that even the federal government does not have with regarding drug
pricing. Arbitration creates opportunity for greater communication, honesty,
and openness that enables the consumer class to prove the scope of the demand
they create for the product, which may incentivize Mylan to respond in order
to maintain that demand and Mylan must respond in order to maintain this
group of consumers.
V. CONCLUSION
Pharmaceutical companies have control over price-setting, and
without leveraging buyer power, consumers will continue to be a price-taker
within the healthcare industry. Prices will continue to rise, and necessary
drugs will become priced out of the reach of the consumers that need them.
Rather than litigation, alternative dispute resolution in this class action will
demonstrate to Mylan and other pharmaceutical companies that consumers
should be the focus of the industry, and companies will only ignore their
consumers at their own financial peril.
ADR opens communication between the parties, allowing this class of
consumers to prove they create the demand for the EpiPen and without their
purchase, Mylan would lose many of its profits. Though mediation is the
method most likely to lead to a creative and unique solutions, arbitration is
most likely to lead to an actual settlement between the parties. An arbitrator
will listen to both sides, weighing all legal and policy related arguments, and
craft a binding solution without the monetary, and emotional costs of
litigation.
The healthcare industry is a web of individuals, groups, organizations,
and businesses centered around the patient and consumer. ADR in this class
action invites the consumer to the table, puts the consumer at the center of the
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healthcare field, and models how other facets of the health care industry can
follow the pharmaceutical ead.
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